Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2021 10:49 ET | Source: Moore Kuehn

Moore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law Firm

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
February 18, 2021 08:30 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
October 28, 2020 08:00 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020

WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
September 24, 2020 08:00 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
August 31, 2020 16:05 ET | Source: Pandion Therapeutics, Inc.

Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update

- Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024 - Expanded executive team with appointment of John S. Sundy, M.D.,...
July 16, 2020 21:01 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics Announces Pricing of Initial Public Offering

WATERTOWN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...